Screening of Syndecan-2-Targeting Antibodies

Virtual Event: Screening of Syndecan-2-Targeting Antibodies That Selectively Block VEGF-A-Induced Vascular Hyperpermeability Using the xCELLigence RTCA eSight System 

Vascular hyperpermeability contributes to pathogenesis in multiple diseases including ischemic stroke, acute MI, and wet AMD.  Although VEGF-A is a key inducer of hyperpermeability, current anti-VEGF-A/VEGFR2 therapies also eliminate VEGF-A's beneficial effects, limiting their use in diseases like stroke. To address this limitation, we have screened hundreds of antibodies targeting Syndecan-2, a VEGFR2 coreceptor, to selectively block VEGF-A-induced vascular permeability while maintaining VEGF-A's protective functions.

To accomplish this, we utilized the xCELLigence RTCA eSight and optimized an in vitro protocol to measure trans-endothelial electrical resistance (TEER) as a model of vascular permeability. We systematically evaluated multiple primary endothelial cell types and established cell lines (e.g. HUVECs, HMLECs, bEnd.3 cells and others), under various experimental conditions. Through this comprehensive approach, we discovered that studying permeability with a TEER assay in vitro requires careful consideration of multiple variables and experimental parameters.

Key Learnings:

• The basics of the TEER assay for studying vascular permeability in vitro
• Optimization and validation of a TEER protocol
• Troubleshooting and feedback from in vivo models of vascular leak

Who should attend:

• Graduate Students
• Postdoctoral Researchers (Postdocs)
• Senior Scientists
• Research Associates
• Principal Investigators (PIs)
• Directors
• Lab Managers
• Research Technicians
• Lab Analysts

Access Featured Resources

To access the complimentary materials, please ensure you’re registered for the event. After registering, click “View Agenda” and navigate to the “Resources” tab to download the files.

Note: You must opt in on the registration form to view these resources. 

Resource 1: Cell Barrier Function Application Page – Cell Analysis | Agilent
 Outlines how Agilent’s xCELLigence RTCA technology, measures and monitor cell barrier integrity in real time, enabling researchers to study endothelial and epithelial barrier dynamics in health and disease.

Resource 2: Anti-Syndecan 2 Antibody Treatment Reduces Edema Formation and Inflammation of Murine Laser-Induced CNV – PMC
 Preclinical study demonstrating that anti-Syndecan-2 antibodies reduce vascular leakage, edema, and inflammation in a murine choroidal neovascularization model, supporting Syndecan-2 as a therapeutic target.

Resource 3: Syndecan-2 Selectively Regulates VEGF-Induced Vascular Permeability – PMC
 Explains how Syndecan-2, as a VEGFR2 coreceptor, selectively modulates VEGF-A–induced vascular permeability while preserving VEGF’s protective effects, enabling targeted reduction of pathological leakage.